Peoples Financial Services CORP. Sells 164 Shares of Johnson & Johnson (NYSE:JNJ)

Peoples Financial Services CORP. lowered its position in Johnson & Johnson (NYSE:JNJGet Rating) by 0.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,645 shares of the company’s stock after selling 164 shares during the quarter. Johnson & Johnson comprises approximately 2.2% of Peoples Financial Services CORP.’s investment portfolio, making the stock its 9th biggest holding. Peoples Financial Services CORP.’s holdings in Johnson & Johnson were worth $4,553,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in JNJ. Family CFO Inc acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $26,000. RE Dickinson Investment Advisors LLC increased its stake in shares of Johnson & Johnson by 163.3% in the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock valued at $28,000 after purchasing an additional 98 shares during the period. Advanced Research Investment Solutions LLC increased its stake in shares of Johnson & Johnson by 200.0% during the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after acquiring an additional 120 shares during the period. Professional Financial Advisors LLC increased its stake in shares of Johnson & Johnson by 47.9% during the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after acquiring an additional 68 shares during the period. Finally, Joseph P. Lucia & Associates LLC acquired a new position in shares of Johnson & Johnson during the first quarter valued at approximately $38,000. Institutional investors and hedge funds own 68.59% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Citigroup lowered their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating on the stock in a research note on Monday, September 12th. UBS Group lowered their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Wells Fargo & Company lifted their price target on shares of Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 13th. Finally, Daiwa Capital Markets assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $189.78.

Johnson & Johnson Trading Up 1.5 %

Johnson & Johnson stock opened at $167.60 on Friday. The company has a 50 day moving average price of $168.96 and a 200 day moving average price of $174.23. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.17 and a current ratio of 1.42. The firm has a market capitalization of $440.65 billion, a price-to-earnings ratio of 24.40, a P/E/G ratio of 2.95 and a beta of 0.61.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The firm had revenue of $24.02 billion during the quarter, compared to analyst estimates of $23.85 billion. During the same quarter last year, the business posted $2.48 EPS. The company’s revenue was up 3.0% on a year-over-year basis. Research analysts forecast that Johnson & Johnson will post 10.7 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.70%. The ex-dividend date was Monday, August 22nd. Johnson & Johnson’s dividend payout ratio is 65.79%.

Johnson & Johnson announced that its Board of Directors has initiated a share repurchase plan on Wednesday, September 14th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the company to buy up to 1.2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.